ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Chicago, IL, USA:

Locations recently updated

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chicago, Illinois, United States and 43 other locations

Recently updated

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Platinum-Based Doublet

Phase 2

Gilead Sciences
Gilead Sciences

Chicago, Illinois, United States and 29 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 209 other locations

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 3

Arcus Biosciences
Arcus Biosciences

Hinsdale, Illinois, United States and 167 other locations

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...

Active, not recruiting
Stage IIIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Radiation: Radiotherapy
Drug: Durvalumab

Phase 2

Alliance Foundation Trials

Chicago, Illinois, United States and 8 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Carboplatin
Drug: Datopotamab Deruxtecan

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Niles, Illinois, United States and 200 other locations

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Paclitaxel
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 230 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 123 other locations

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Chicago, Illinois, United States and 23 other locations

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Osimertinib
Drug: HER3-DXd

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 30 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems